Monitoring and Improving Adherence to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia: A Systematic Review

被引:11
|
作者
Tan, Bee Kim [1 ]
Chong, Ping [2 ]
Chua, Siew Siang [1 ]
Chen, Li-Chia [3 ]
机构
[1] Taylors Univ, Fac Hlth & Med Sci, Sch Pharm, Subang Jaya 47500, Selangor, Malaysia
[2] Univ Malaya, Fac Med, Dept Med, Kuala Lumpur 50603, Malaysia
[3] Univ Manchester, Manchester Acad Hlth Sci Ctr, Fac Biol,Div Pharm & Optometry, Sch Hlth Sci,Ctr Pharmacoepidemiol & Drug Safety, Manchester M13 9PT, Lancs, England
来源
关键词
medication adherence; tyrosine kinase inhibitors; chronic myeloid leukemia; systematic review; complex interventions; IMATINIB; THERAPY; IMPACT; COSTS; SUPPRESSION; DASATINIB; NILOTINIB;
D O I
10.2147/PPA.S269355
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Suboptimal adherence to tyrosine kinase inhibitors (TKIs) is a widely recognized issue compromising the disease control and survival of patients with chronic myeloid leukemia (CML). A recently published review by Heiney et al reported inconclusive findings on the effects of a broad range of adherence enhancing interventions. The current systematic review aimed to identify studies that evaluated adherence-enhancing interventions implemented by healthcare professionals and determine their effect on CML patients' medication adherence and clinical outcomes. Methods: A systematic literature search was performed in 5 databases for articles published between 2002 and 2021. Studies that compared adherence enhancing interventions implemented by healthcare professionals with a comparison group were included. Relevant data on study characteristics were extracted. Medication adherence and clinical outcomes between intervention and control arms were compared. Results: Nine studies were included in two randomised controlled trials, four cohort studies, and three before-and-after comparison studies. All the included studies incorporated complex interventions, including intensive education or consultation with pharmacists, nurses or multidisciplinary team, in combination with one or more other strategies such as structured follow-up, written materials or video, psychotherapy, medication reminder or treatment diary, with the overall goal of monitoring and improving TKI adherence. Most (7 out of 9) studies demonstrated significantly better adherence to TKIs in the intervention group than the comparison group. The relative proportion of participants who adhered to TKIs ranged from 1.22 to 2.42. The improvement in the rate of TKI doses taken/received ranged from 1.5% to 7.1%. Only one study showed a significant association between intervention and clinical outcomes, with a 22.6% higher major molecular response rate and improvement in 6 out of 20 subscales of health-related quality-of-life. Conclusion: Complex interventions delivered by healthcare professionals showed improvement in adherence to TKIs in CML patients. Further studies are required to clarify the costeffectiveness of adherence-enhancing interventions.
引用
收藏
页码:2563 / 2575
页数:13
相关论文
共 50 条
  • [1] Interventions to Improve Adherence to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia A Systematic Review
    Heiney, Sue P.
    Sorrell, McKenzie
    Sheng, Jingxi
    Adams, Swann A.
    Nelson, Kathy
    Nguyen, Lan A.
    Edwards, Amy
    Wickersham, Karen E.
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2021, 44 (06): : 291 - 298
  • [2] Laboratory Monitoring of Chronic Myeloid Leukemia in Patients on Tyrosine Kinase Inhibitors
    Richa Chauhan
    Sudha Sazawal
    H. P. Pati
    [J]. Indian Journal of Hematology and Blood Transfusion, 2018, 34 : 197 - 203
  • [3] Laboratory Monitoring of Chronic Myeloid Leukemia in Patients on Tyrosine Kinase Inhibitors
    Chauhan, Richa
    Sazawal, Sudha
    Pati, H. P.
    [J]. INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2018, 34 (02) : 197 - 203
  • [4] Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia
    Dusetzina, Stacie B.
    Winn, Aaron N.
    Abel, Gregory A.
    Huskamp, Haiden A.
    Keating, Nancy L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04) : 306 - 311
  • [5] Glycemic Control in Patients Treated with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: A Systematic Review
    Spatafora, Laura
    Golemiec, Breanne
    Thabane, Lehana
    Banfield, Laura
    Hillis, Christopher M.
    Samaan, Constantine
    Athale, Uma
    [J]. BLOOD, 2018, 132
  • [6] Tyrosine kinase inhibitors concentration monitoring in chronic myeloid leukemia
    Widmer, N.
    Gotta, V.
    Haouala, A.
    Decosterd, L. A.
    [J]. LEUKEMIA RESEARCH, 2010, 34 (06) : 698 - 699
  • [7] Chronic myeloid leukemia patients' adherence to peroral tyrosine kinase inhibitors compared with adherence as estimated by their physicians
    Kekale, Meri
    Talvensaari, Kimmo
    Koskenvesa, Perttu
    Porkka, Kimmo
    Airaksinen, Marja
    [J]. PATIENT PREFERENCE AND ADHERENCE, 2014, 8 : 1619 - 1627
  • [8] Tyrosine kinase inhibitors for elderly chronic myeloid leukemia patients: A systematic review of efficacy and safety data
    Breccia, Massimo
    Tiribelli, Mario
    Alimena, Giuliana
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2012, 84 (01) : 93 - 100
  • [9] A safety review of tyrosine kinase inhibitors for chronic myeloid leukemia
    Oezmen, Deniz
    Alpaydin, Duygu Demet
    Saldogan, Muhammed Ali
    Eskazan, Ahmet Emre
    [J]. EXPERT OPINION ON DRUG SAFETY, 2024, 23 (04) : 411 - 423
  • [10] Side effects and medication adherence of tyrosine kinase inhibitors for patients with chronic myeloid leukemia in Taiwan
    Tsai, Yu-Fen
    Huang, Wen-Chuan
    Cho, Shih-Feng
    Hsiao, Hui-Hua
    Liu, Yi-Chang
    Lin, Sheng-Fung
    Liu, Ta-Chih
    Chang, Chao-Sung
    [J]. MEDICINE, 2018, 97 (26)